---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-24-022186"
form_type: "8-K"
ticker: "SGMO"
cik: "0001001233"
company_name: "SANGAMO THERAPEUTICS, INC"
filed_at: "2024-05-09T23:59:59+00:00"
generated_at: "2026-06-02T04:37:27.400912+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Sangamo Q1 net loss $49.1M on revenue collapse to $0.5M from $158M; cash runway only into Q3 2024

## Summary
- Net loss of $49.1M vs net income $21.1M YoY; diluted EPS -$0.27 vs +$0.12.
- Revenue fell to $0.5M from $158M, driven by termination of Biogen/Novartis collaborations.
- Cash $54.4M at March 31 (down from $81M); raised ~$24M gross via direct offering.
- Pfizer expects BLA/MAA submission for hemophilia A gene therapy in early 2025 if mid-2024 pivotal readout positive.
- Fabry gene therapy STAAR study fully dosed; seeking collaboration partner before registrational trial.

## SEC filing metadata
- accession: 0001628280-24-022186
- form_type: 8-K
- ticker: SGMO
- cik: 0001001233
- company_name: SANGAMO THERAPEUTICS, INC
- filed_at: 2024-05-09T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1001233/000162828024022186/0001628280-24-022186-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1001233/000162828024022186/sgmo-20240509.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-24-022186
- JSON: https://secwatch.observer/filing/0001628280-24-022186.json
- Plain text: https://secwatch.observer/filing/0001628280-24-022186.txt

## Key facts
- Earnings Releases
  SANGAMO THERAPEUTICS, INC reported financial results for the quarter ended March 31, 2024.
  - Period: the quarter ended March 31, 2024
  - Result: reported results
  source text: On May 9, 2024, Sangamo Therapeutics, Inc. (“Sangamo”) issued a press release announcing its financial results for the quarter ended March 31, 2024 (the “Press Release”).
  evidence_url: https://www.sec.gov/Archives/edgar/data/1001233/000162828024022186/0001628280-24-022186-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.